BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby

Dow Jones2024-11-25

By Adriano Marchese

BridgeBio Pharma shares jumped in premarket trading Monday after it received regulatory approval in the U.S. for its treatment for patients with transthyretin amyloid cardiomyopathy.

Shares traded over 25% higher ahead of the morning bell at $29.35.

The Palo Alto, California-based biopharmaceutical company said the Food and Drug Administration approved Attruby for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalization.

ATTR-CM affects the heart by depositing clumps of protein in the heart tissue which can affect the heart's ability to function properly and could lead to heart failure.

The FDA approved the treatment based on positive results seen in the its phase-3 study that showed Attruby significantly reduced death and cardiovascular-related hospitalization.

Additionally, BridgeBio said it submitted a marketing authorization application for the drug to the European Medicines Agency, and expects a decision sometime next year. The company has granted exclusive rights to Bayer to commercialize the drug for ATTR-CM in Europe.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 25, 2024 09:10 ET (14:10 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486108229?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-25 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486108229","market":"sh","top_or_hot":-1,"title":"BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  BridgeBio Pharma shares jumped in premarket trading Monday after it received regulatory approval in the U.S. for its treatment for patients with transthyretin amyloid cardiomyopathy. \n</p>\n<p>\n  Shares traded over 25% higher ahead of the morning bell at $29.35. \n</p>\n<p>\n  The Palo Alto, California-based biopharmaceutical company said the Food and Drug Administration approved Attruby for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalization. \n</p>\n<p>\n   ATTR-CM affects the heart by depositing clumps of protein in the heart tissue which can affect the heart's ability to function properly and could lead to heart failure. \n</p>\n<p>\n  The FDA approved the treatment based on positive results seen in the its phase-3 study that showed Attruby significantly reduced death and cardiovascular-related hospitalization. \n</p>\n<p>\n  Additionally, BridgeBio said it submitted a marketing authorization application for the drug to the European Medicines Agency, and expects a decision sometime next year. The company has granted exclusive rights to Bayer to commercialize the drug for ATTR-CM in Europe. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 25, 2024 09:10 ET (14:10 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 22:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Adriano Marchese \n\n\n \n\n\n  BridgeBio Pharma shares jumped in premarket trading Monday after it received regulatory approval in the U.S. for its treatment for patients with transthyretin amyloid ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBIO","symbol_name":"BridgeBio Pharma, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2486108229","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486108229","pubTimestamp":1732543800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BridgeBio Pharma shares jumped in premarket trading Monday after it received regulatory approval in the U.S. for its treatment for patients with transthyretin amyloid cardiomyopathy.Shares traded over 25% higher ahead of the morning bell at $29.35.The Palo Alto, California-based biopharmaceutical company said the Food and Drug Administration approved Attruby for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalization.The FDA approved the treatment based on positive results seen in the its phase-3 study that showed Attruby significantly reduced death and cardiovascular-related hospitalization.Additionally, BridgeBio said it submitted a marketing authorization application for the drug to the European Medicines Agency, and expects a decision sometime next year. The company has granted exclusive rights to Bayer to commercialize the drug for ATTR-CM in Europe.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BBIO":"BridgeBio Pharma, Inc.","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4588":"碎股"},"translate_title":"BridgeBio Pharma心脏病药物Attruby获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  BridgeBio Pharma shares jumped in premarket trading Monday after it received regulatory approval in the U.S. for its treatment for patients with transthyretin amyloid cardiomyopathy. \n\n\n  Shares traded over 25% higher ahead of the morning bell at $29.35. \n\n\n  The Palo Alto, California-based biopharmaceutical company said the Food and Drug Administration approved Attruby for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalization. \n\n\n   ATTR-CM affects the heart by depositing clumps of protein in the heart tissue which can affect the heart's ability to function properly and could lead to heart failure. \n\n\n  The FDA approved the treatment based on positive results seen in the its phase-3 study that showed Attruby significantly reduced death and cardiovascular-related hospitalization. \n\n\n  Additionally, BridgeBio said it submitted a marketing authorization application for the drug to the European Medicines Agency, and expects a decision sometime next year. The company has granted exclusive rights to Bayer to commercialize the drug for ATTR-CM in Europe. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2024 09:10 ET (14:10 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486108229"}